€287.08
0.31% day before yesterday
L&S, Jul 05, 10:55 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$310.88
+3.50 1.14% 1M
+7.88 2.60% 6M
+22.86 7.94% YTD
+85.00 37.63% 1Y
+62.18 25.00% 3Y
+124.94 67.19% 5Y
+190.72 158.72% 10Y
NYSE, Closing price Fri, Jul 05 2024
+1.50 0.48%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Market capitalization $166.77b
Enterprise Value $221.08b
PER (TTM) P/E ratio 44.46
EV/FCF (TTM) EV/FCF 31.15
EV/Sales (TTM) EV/Sales 7.53
P/S ratio (TTM) P/S ratio 5.68
P/B ratio (TTM) P/B ratio 33.21
Dividend yield 2.74%
Last dividend (FY23) $8.52
Revenue growth (TTM) Revenue growth 13.18%
Revenue (TTM) Revenue $29.35b
EBIT (operating result TTM) EBIT $7.29b
Free Cash Flow (TTM) Free Cash Flow $7.10b
Cash position $9.71b
EPS (TTM) EPS $6.99
P/E forward 36.11
P/S forward 5.05
EV/Sales forward 6.70
Short interest 1.70%
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Analyst Opinions

29 Analysts have issued a Amgen forecast:

14x Buy
48%
13x Hold
45%
2x Sell
7%

Analyst Opinions

29 Analysts have issued a Amgen forecast:

Buy
48%
Hold
45%
Sell
7%

Financial data from Amgen

Mar '24
+/-
%
Net Profit -113 -113
104% 104%
-2%
Depreciation and Amortization 1,399 1,399
55% 55%
19%
Stock Compensation 103 103
-
1%
Operating Cash Flow 689 689
35% 35%
9%
Investments 230 230
33% 33%
3%
Dividend Paid 1,208 1,208
6% 6%
16%
Free Cash Flow 459 459
36% 36%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Positive
Seeking Alpha
one day ago
Amgen shares have outperformed IBB by over 40% in the past year, driven higher by a major surge post-earnings in May. With a current price-to-earnings multiple in the mid-teens, I assert that solid and consistent EPS growth ahead warrants a higher valuation. AMGN's chart is also impressive, with a long-term uptrend in place.
Positive
InvestorPlace
2 days ago
The COVID-19 pandemic emphasized the importance of healthcare companies. Consistent breakthroughs, improved products and relatively consistent growth make these companies fan-favorite picks for investors.
Positive
The Motley Fool
3 days ago
Amgen is much cheaper than Eli Lilly. Vertex Pharmaceuticals has several major growth drivers.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 26,700
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today